Investment analysts at StockNews.com assumed coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) in a note issued to investors on Saturday. The firm set a "hold" rating on the biopharmaceutical company's stock.
Other equities research analysts have also issued reports about the stock. Royal Bank of Canada reissued a "sector perform" rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Leerink Partnrs cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Finally, Piper Sandler reissued a "neutral" rating and issued a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Eleven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of "Hold" and an average price target of $106.23.
View Our Latest Analysis on Intra-Cellular Therapies
Intra-Cellular Therapies Price Performance
Shares of ITCI remained flat at $131.87 during trading hours on Friday. Intra-Cellular Therapies has a 1-year low of $64.09 and a 1-year high of $131.98. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The stock's 50-day moving average is $129.71 and its 200-day moving average is $102.19.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, sell-side analysts anticipate that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Intra-Cellular Therapies
Several institutional investors have recently made changes to their positions in ITCI. China Universal Asset Management Co. Ltd. raised its stake in Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after buying an additional 2,157 shares during the period. Barclays PLC raised its position in shares of Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after purchasing an additional 25,435 shares during the period. Oak Ridge Investments LLC lifted its holdings in shares of Intra-Cellular Therapies by 74.1% in the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after purchasing an additional 8,440 shares in the last quarter. Principal Financial Group Inc. grew its position in Intra-Cellular Therapies by 3.3% in the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock valued at $43,735,000 after purchasing an additional 18,865 shares during the period. Finally, Merit Financial Group LLC bought a new stake in Intra-Cellular Therapies during the 4th quarter valued at $206,000. Institutional investors and hedge funds own 92.33% of the company's stock.
Intra-Cellular Therapies Company Profile
(
Get Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Further Reading
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
